Skip to main content
Premium Trial:

Request an Annual Quote

Sequencing Technology Developer Omniome Raises $60M in Series B

NEW YORK (GenomeWeb) – Omniome, which his developing a new DNA sequencing technology, has raised $60 million in a Series B financing round, the company said today.

The round was led by Decheng Capital and Hillhouse Capital. They were joined by new investors Lam Research Capital and Nan Fung Life Sciences and by current investors ARCH Venture Partners, Domain Associates, Biomatics Capital Partners, and Altitude Life Science Ventures.

The San Diego-based company is developing a new sequencing platform that relies on so-called Sequencing By Binding technology and promises to provide highly accurate and fast results at low cost.

Omniome plans to use the proceeds in part to hire staff in several areas, particularly engineering, and to increase its research and production capacity.  It will continue to optimize its technology and accelerate prototype development.

Dave Mullarkey, the company's president and CEO, said in a statement that Omniome has validated its sequencing biochemistry. "Now we are directing our efforts on product development to rapidly advance our first commercial instrument prototypes." He is the former president and chief operating officer of Ariosa Diagnostics.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.